AIMS/HYPOTHESIS: Subcellular localisation is an important factor in the known impact of bioactive lipids, such as diacylglycerol and sphingolipids, on insulin sensitivity in skeletal muscle; yet, the role of localised intramuscular triacylglycerol (IMTG) is yet to be described. Excess accumulation of IMTG in skeletal muscle is associated with insulin resistance, and we hypothesised that differences in subcellular localisation and composition of IMTG would relate to metabolic health status in humans. METHODS: We evaluated subcellular localisation of IMTG in lean participants, endurance-trained athletes, individuals with obesity and individuals with type 2 diabetes using LC-MS/MS of fractionated muscle biopsies and insulin clamps. RESULTS: Insulin sensitivity was significantly different between each group (athletes>lean>obese>type 2 diabetes; p < 0.001). Sarcolemmal IMTG was significantly greater in individuals with obesity and type 2 diabetes compared with lean control participants and athletes, but individuals with type 2 diabetes were the only group with significantly increased saturated IMTG. Sarcolemmal IMTG was inversely related to insulin sensitivity. Nuclear IMTG was significantly greater in individuals with type 2 diabetes compared with lean control participants and athletes, and total and saturated IMTG localised in the nucleus had a significant inverse relationship with insulin sensitivity. Total cytosolic IMTG was not different between groups, but saturated cytosolic IMTG species were significantly increased in individuals with type 2 diabetes compared with all other groups. There were no significant differences between groups for IMTG concentration in the mitochondria/endoplasmic reticulum. CONCLUSIONS/ INTERPRETATION: These data reveal previously unknown differences in subcellular IMTG localisation based on metabolic health status and indicate the influence of sarcolemmal and nuclear IMTG on insulin sensitivity. Additionally, these studies suggest saturated IMTG may be uniquely deleterious for muscle insulin sensitivity. Graphical abstract.
AIMS/HYPOTHESIS: Subcellular localisation is an important factor in the known impact of bioactive lipids, such as diacylglycerol and sphingolipids, on insulin sensitivity in skeletal muscle; yet, the role of localised intramuscular triacylglycerol (IMTG) is yet to be described. Excess accumulation of IMTG in skeletal muscle is associated with insulin resistance, and we hypothesised that differences in subcellular localisation and composition of IMTG would relate to metabolic health status in humans. METHODS: We evaluated subcellular localisation of IMTG in lean participants, endurance-trained athletes, individuals with obesity and individuals with type 2 diabetes using LC-MS/MS of fractionated muscle biopsies and insulin clamps. RESULTS: Insulin sensitivity was significantly different between each group (athletes>lean>obese>type 2 diabetes; p < 0.001). Sarcolemmal IMTG was significantly greater in individuals with obesity and type 2 diabetes compared with lean control participants and athletes, but individuals with type 2 diabetes were the only group with significantly increased saturated IMTG. Sarcolemmal IMTG was inversely related to insulin sensitivity. Nuclear IMTG was significantly greater in individuals with type 2 diabetes compared with lean control participants and athletes, and total and saturated IMTG localised in the nucleus had a significant inverse relationship with insulin sensitivity. Total cytosolic IMTG was not different between groups, but saturated cytosolic IMTG species were significantly increased in individuals with type 2 diabetes compared with all other groups. There were no significant differences between groups for IMTG concentration in the mitochondria/endoplasmic reticulum. CONCLUSIONS/ INTERPRETATION: These data reveal previously unknown differences in subcellular IMTG localisation based on metabolic health status and indicate the influence of sarcolemmal and nuclear IMTG on insulin sensitivity. Additionally, these studies suggest saturated IMTG may be uniquely deleterious for muscle insulin sensitivity. Graphical abstract.
Authors: D A Pan; S Lillioja; A D Kriketos; M R Milner; L A Baur; C Bogardus; A B Jenkins; L H Storlien Journal: Diabetes Date: 1997-06 Impact factor: 9.461
Authors: M Krssak; K Falk Petersen; A Dresner; L DiPietro; S M Vogel; D L Rothman; M Roden; G I Shulman Journal: Diabetologia Date: 1999-01 Impact factor: 10.122
Authors: Clinton R Bruce; A Brianne Thrush; Valerie A Mertz; Veronic Bezaire; Adrian Chabowski; George J F Heigenhauser; David J Dyck Journal: Am J Physiol Endocrinol Metab Date: 2006-02-07 Impact factor: 4.310
Authors: John J Dubé; Francesca Amati; Maja Stefanovic-Racic; Frederico G S Toledo; Sarah E Sauers; Bret H Goodpaster Journal: Am J Physiol Endocrinol Metab Date: 2008-03-04 Impact factor: 4.310
Authors: C S Shaw; S O Shepherd; A J M Wagenmakers; D Hansen; P Dendale; L J C van Loon Journal: Am J Physiol Endocrinol Metab Date: 2012-09-04 Impact factor: 4.310
Authors: G Perseghin; P Scifo; F De Cobelli; E Pagliato; A Battezzati; C Arcelloni; A Vanzulli; G Testolin; G Pozza; A Del Maschio; L Luzi Journal: Diabetes Date: 1999-08 Impact factor: 9.461
Authors: Josiane L Broussard; Leigh Perreault; Emily Macias; Sean A Newsom; Kathleen Harrison; Hai Hoang Bui; Paul Milligan; Kenneth D Roth; Travis Nemkov; Angelo D'Alessandro; Joseph T Brozinick; Bryan C Bergman Journal: Obesity (Silver Spring) Date: 2021-03 Impact factor: 5.002
Authors: Laura L Gathercole; Nikolaos Nikolaou; Shelley E Harris; Anastasia Arvaniti; Toryn M Poolman; Jonathan M Hazlehurst; Denise V Kratschmar; Marijana Todorčević; Ahmad Moolla; Niall Dempster; Ryan C Pink; Michael F Saikali; Liz Bentley; Trevor M Penning; Claes Ohlsson; Carolyn L Cummins; Matti Poutanen; Alex Odermatt; Roger D Cox; Jeremy W Tomlinson Journal: J Endocrinol Date: 2022-04-13 Impact factor: 4.669
Authors: Kelli A Rosen; Anay Thodge; Amy Tang; Brendan M Franz; Chad L Klochko; Steven B Soliman Journal: BMC Endocr Disord Date: 2022-07-27 Impact factor: 3.263